Literature DB >> 11268227

Early switch from intravenous to oral antibiotics in hospitalized patients with bacteremic community-acquired Streptococcus pneumoniae pneumonia.

J A Ramirez1, J Bordon.   

Abstract

BACKGROUND: The identification of Streptococcus pneumoniae bacteremia in hospitalized patients with community-acquired pneumonia is considered by some investigators to be an exclusion criterion for early switch from intravenous to oral therapy.
OBJECTIVE: To determine whether the switch from intravenous to oral therapy in such patients, once the bx;1patient reaches clinical stability, is associated with poor clinical outcome.
METHODS: The medical records of 400 patients with community-acquired pneumonia hospitalized at the Veterans Affairs Medical Center of Louisville (Louisville, Ky) were reviewed to identify patients with bacteremic S pneumoniae. Four criteria were used to define when a patient reached clinical stability and should be considered a candidate for switch therapy: (1) cough and shortness of breath are improving, (2) patient is afebrile for at least 8 hours, (3) white blood cell count is normalizing, and (4) oral intake and gastrointestinal tract absorption are adequate.
RESULTS: A total of 36 bacteremic patients were identified. No clinical failures occurred in 18 patients who reached clinical stability and were switched to oral therapy or in 7 patients who reached clinical stability and continued intravenous therapy. Clinical failures (5 deaths) occurred in the group of 11 patients who did not reach clinical stability.
CONCLUSION: Once a hospitalized patient with community-acquired pneumonia reaches clinical stability, it is safe to switch from intravenous to oral antibiotics even if bacteremia caused by S pneumoniae was initially documented.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11268227     DOI: 10.1001/archinte.161.6.848

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  25 in total

Review 1.  Bacteraemic pneumococcal pneumonia: current therapeutic options.

Authors:  Charles Feldman; Ronald Anderson
Journal:  Drugs       Date:  2011-01-22       Impact factor: 9.546

2.  Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults.

Authors:  Lionel A Mandell; Richard G Wunderink; Antonio Anzueto; John G Bartlett; G Douglas Campbell; Nathan C Dean; Scott F Dowell; Thomas M File; Daniel M Musher; Michael S Niederman; Antonio Torres; Cynthia G Whitney
Journal:  Clin Infect Dis       Date:  2007-03-01       Impact factor: 9.079

3.  A tailored implementation strategy to reduce the duration of intravenous antibiotic treatment in community-acquired pneumonia: a controlled before-and-after study.

Authors:  M F Engel; A H W Bruns; M E J L Hulscher; C A J M Gaillard; S U C Sankatsing; F Teding van Berkhout; M H Emmelot-Vonk; E M Kuck; M H M Steeghs; J H den Breeijen; R K Stellato; A I M Hoepelman; J J Oosterheert
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-05-26       Impact factor: 3.267

4.  Modern Management of Community-Acquired Pneumonia: Is It Cost-Effective and are Outcomes Acceptable?

Authors:  Dominik Mertz; Jennie Johnstone
Journal:  Curr Infect Dis Rep       Date:  2011-06       Impact factor: 3.725

5.  Implementation of guidelines for sequential therapy with fluoroquinolones in a Belgian hospital.

Authors:  Franky Buyle; Dirk Vogelaers; Renaat Peleman; Georges Van Maele; Hugo Robays
Journal:  Pharm World Sci       Date:  2010-04-01

6.  Effect of prior pneumococcal vaccination on clinical outcome of hospitalized adults with community-acquired pneumococcal pneumonia.

Authors:  A Mykietiuk; J Carratalà; A Domínguez; A Manzur; N Fernández-Sabé; J Dorca; F Tubau; F Manresa; F Gudiol
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-07       Impact factor: 3.267

7.  Treatment failure and costs in patients with methicillin-resistant Staphylococcus aureus (MRSA) skin and soft tissue infections: a South Texas Ambulatory Research Network (STARNet) study.

Authors:  Matthew J Labreche; Grace C Lee; Russell T Attridge; Eric M Mortensen; Jim Koeller; Liem C Du; Natalie R Nyren; Lucina B Treviño; Sylvia B Treviño; Joel Peña; Michael W Mann; Abilio Muñoz; Yolanda Marcos; Guillermo Rocha; Stella Koretsky; Sandra Esparza; Mitchell Finnie; Steven D Dallas; Michael L Parchman; Christopher R Frei
Journal:  J Am Board Fam Med       Date:  2013 Sep-Oct       Impact factor: 2.657

8.  Bacteremic pneumococcal pneumonia: clinical outcomes and preliminary results of inflammatory response.

Authors:  J M Bordon; R Fernandez-Botran; T L Wiemken; P Peyrani; S M Uriarte; F W Arnold; L Rodriquez-Hernandez; M J Rane; R R Kelley; L E Binford; S Uppatla; R Cavallazzi; F Blasi; S Aliberti; M I Restrepo; S Fazeli; A Mathur; M Rahmani; K Ayesu; J Ramirez
Journal:  Infection       Date:  2015-09-30       Impact factor: 3.553

9.  Fluoroquinolone versus Beta-Lactam Oral Step-Down Therapy for Uncomplicated Streptococcal Bloodstream Infections.

Authors:  Kellie Arensman; Maureen Shields; Maya Beganovic; Jessica L Miller; Erik LaChance; Morgan Anderson; Jennifer Dela-Pena
Journal:  Antimicrob Agents Chemother       Date:  2020-10-20       Impact factor: 5.191

10.  Outcomes of early switching from intravenous to oral antibiotics on medical wards.

Authors:  Dominik Mertz; Michael Koller; Patricia Haller; Markus L Lampert; Herbert Plagge; Balthasar Hug; Gian Koch; Manuel Battegay; Ursula Flückiger; Stefano Bassetti
Journal:  J Antimicrob Chemother       Date:  2009-04-28       Impact factor: 5.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.